What is GeNO?
GeNO LLC is a biopharmaceutical innovator specializing in inhaled nitric oxide (NO) therapies. The company's core innovation lies in its proprietary GeNOsyl® drug delivery technology, which utilizes a unique chemistry-first approach to generate NO with minimized nitrogen dioxide (NO2) byproduct. This system is designed for both acute hospital settings and long-term outpatient applications, offering a portable console or wearable controller for safe and effective NO administration. GeNO's lead product, GeNOsyl Acute DS, aims to improve therapeutic outcomes for ventilated patients and those requiring NO via nasal cannula or face mask. The company's scientific foundation is built upon overcoming the limitations of conventional NO delivery methods, which often suffer from significant NO2 co-delivery due to dilution-based kinetics. GeNO's approach chemically generates NO, enhancing safety and efficacy. With two active Investigational New Drug Applications (INDs), GeNO is exploring NO's potential in diagnostics for pulmonary arterial hypertension and other therapeutic areas, positioning itself as a key player in advanced respiratory and cardiovascular treatments.
How much funding has GeNO raised?
GeNO has raised a total of $54.8M across 4 funding rounds:
Private Equity
$2.1M
Private Equity
$8M
Private Equity
$14.7M
Private Equity
$29.9M
Private Equity (2009): $2.1M, investors not publicly disclosed
Private Equity (2011): $8M, investors not publicly disclosed
Private Equity (2013): $14.7M, investors not publicly disclosed
Private Equity (2017): $29.9M, investors not publicly disclosed
What's next for GeNO?
The substantial enterprise-level funding and recent strategic investment provide GeNO with significant capital to accelerate its development pipeline and commercialization efforts. The company is poised to advance its clinical studies, particularly those exploring the diagnostic and therapeutic applications of its inhaled nitric oxide system. With a focus on its differentiated technology and user-friendly solutions, GeNO is strategically positioned to address critical unmet needs in pulmonary and cardiac disease management. Future growth will likely involve expanding its IND applications, securing further strategic partnerships, and navigating the regulatory pathway towards market approval, solidifying its presence in the biopharmaceutical sector.
See full GeNO company page
